Systematic and Statistical Review of Coronavirus Disease 19 Treatment Trials

Abstract The following systematic review and meta-analysis compile the current data regarding human controlled COVID-19 treatment trials. An electronic search of the literature compiled studies pertaining to human controlled treatment trials with COVID-19. Medications assessed included lopinavir/ritonavir, arbidol, hydroxychloroquine, tocilizumab, favipiravir, heparin, and dexamethasone. Statistical analyses were performed for common viral clearance endpoints whenever possible. Lopinavir/ritonavir showed no significant effect on viral clearance for COVID-19 cases (OR 0.95 [95% CI 0.50–1.83]). Hydroxychloroquine also showed no significant effect on COVID-19 viral clearance rates (OR 2.16 [95% CI 0.80–5.84]). Arbidol showed no 7-day (OR 1.63 [95% CI 0.76–3.50]) or 14-day viral (OR 5.37 [95% CI 0.35–83.30]) clearance difference compared to lopinavir/ritonavir. Review of literature showed no significant clinical improvement with lopinavir/ritonavir, arbidol, hydroxychloroquine, or remdesivir. Tocilizumab showed mixed results regarding survival. Favipiravir showed quicker symptom improvement compared to lopinavir/ritonavir and arbidol. Heparin and dexamethasone showed improvement with severe COVID-19 cases requiring supplemental oxygenation. Current medications do not show significant effect on COVID-19 viral clearance rates. Tocilizumab showed mixed results regarding survival. Favipiravir shows favorable results compared to other tested medications. Heparin and dexamethasone show benefit especially for severe COVID-19 cases..

Media Type:

Electronic Article

Year of Publication:

2020

Publication:

2020

Contained In:

SN comprehensive clinical medicine - 2(2020), 8 vom: 15. Juli, Seite 1120-1131

Language:

English

Contributors:

Siordia, Juan A. [Author]
Bernaba, Michael [Author]
Yoshino, Kenji [Author]
Ulhaque, Abid [Author]
Kumar, Sooraj [Author]
Bernaba, Mario [Author]
Bergin, Edward [Author]

Links:

Volltext [Lizenzpflichtig]

Keywords:

Arbidol
COVID-19
Coronavirus
Dexamethasone
Favipiravir
Heparin
Hydroxychloroquine
Lopinavir/ritonavir
Remdesivir
SARS-CoV2
Tocilizumab
Treatment
Trials

doi:

10.1007/s42399-020-00399-6

PPN (Catalogue-ID):

SPR040584925